(30 days)
Not Found
Not Found
No
The summary describes a standard blood glucose monitoring system and does not mention any AI or ML capabilities.
No.
The device is an "in vitro diagnostic" device, used for monitoring glucose levels, not for treating any condition.
Yes
The text explicitly states "Testing is done outside the body (in vitro diagnostic use)." and describes the device as an "aid to monitor the effectiveness of diabetes control," both indicating a diagnostic purpose.
No
The device description explicitly lists hardware components such as a meter, batteries, carrying case, lancing device, lancets, and control solution, indicating it is a system with physical components, not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
The intended use statement explicitly states: "Testing is done outside the body (in vitro diagnostic use)." This is a clear indication that the device is designed for in vitro diagnostic purposes.
N/A
Intended Use / Indications for Use
The WaveSense JAZZ 100 Blood Glucose Monitoring System in intended to quantitatively measure blood glucose levels, also known as blood sugar, from fresh capillary whole blood samples taken from the fingertips, palm, or forearem. The WaveSense JAZZ TM Test Strips are for in vitro diagnostic (outside of the body) use only. The WaveSense JAZZ TM System is not for intended for use with neonates.
AgaMatrix JAZZ™ Blood Glucose Monitoring System:
AgaMatrix JAZZ™ Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood from the finger stick, palm, and/or forearm. Testing is done outside the body (in vitro diagnostic use). It is indicated for use at home (over the counter (OTC) ) by persons with diabetes, or in a clinical setting by healthcare professionals, as an aid to monitor the effectiveness of diabetes control.
AgaMatrix JAZZ™ Blood Glucose Meter:
AgaMatrix JAZZ™ Blood Glucose Meter is intended for use with AgaMatrix JAZZ™ Blood Glucose Test Strips for the quantitative measurement of glucose in fresh capillary whole blood from the finger stick, palm, and/or forearm. Testing is done outside the body (in vitro diagnostic use). It is indicated for use at home (over the counter (OTC) ) by persons with diabetes, or in a clinical setting by healthcare professionals, as an aid to monitor the effectiveness of diabetes control.
AgaMatrix JAZZ™ Blood Glucose Test Strips:
AgaMatrix JAZZ™ Blood Glucose Test Strips are intended for use with AgaMatrix JAZZ™ Blood Glucose Meter for the quantitative measurement of glucose in fresh capillary whole blood from the finger stick, palm and/or forearm. Testing is done outside the body (in vitro diagnostic use). It is indicated for use at home (over the counter (OTC) ) by persons with diabetes, or in a clinical setting by healthcare professionals, as an aid to monitor the effectiveness of diabetes control.
AgaMatrix JAZZTM Control Solutions (Normal level and High level):
AgaMatrix JAZZ™ Control Solutions are intended for use with the AgaMatrix JAZZ™ Meter and AgaMatrix JAZZ™ Test Strips as a quality control check to verify the accuracy of blood glucose test results.
Product codes (comma separated list FDA assigned to the subject device)
NBW, CGA, JJX
Device Description
The AgaMatrix WaveSense JAZZ™ Blood Glucose Monitoring System includes a meter with batteries, compact carrying case, Lancing device, lancets, control solution and owner's booklet. Test Strips are sold separately. It is intended for over-the-counter home use by diabetics to monitor their blood glucose levels, or for use in a clinical setting by healthcare professionals. The system tests fresh capillary whole blood. The meter is a portable, battery-operated instrument.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
fingertips, palm, or forearem
Indicated Patient Age Range
The WaveSense JAZZ TM System is not for intended for use with neonates.
Intended User / Care Setting
over-the-counter home use by diabetics / in a clinical setting by healthcare professionals
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Based upon the testing and comparison to the predicate device, the WaveSense JAZZ™ Blood Glucose Monitoring System which does not require coding, has the same intended uses, with similar technological characteristics as the predicate device. The system performs as intended and raises no new safety of effectiveness issues.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
Image /page/0/Picture/0 description: The image shows the logo for AgaMatrix. The logo consists of the word "AgaMatrix" in a simple, sans-serif font. A curved line underlines the word. To the right of the word, there are four small squares arranged in a curved line, suggesting a matrix or a series of data points.
10 Manor Parkway Salem, NH 03079 Office: +1 (603) 328-6000 Fax: =1 (603) 893-4191
JAZZ™ 510 (k) SUMMARY
KN12412
SEP 2 7 2007
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
-
- Submitter's Name, Address, Telephone Number, Contact Person, and date the summary was prepared.
| Submitter's Name: | Connie Hertel
AgaMatrix, Inc.
10 Manor Parkway
Salem, NH 03079 |
|-------------------|-------------------------------------------------------------------------|
| Contact Person: | Connie Hertel
Director Quality & Regulatory Affairs |
| Telephone: | (603) 328-6051 |
| Fax: | (603) 893-4191 |
Date the summary prepared:
August 17, 2007
2. Device Name
| Trade/Propritary Name: | WaveSense JAZZ™ Blood Glucose Monitoring System |
|---|---|
| Common/Usual Name: | Blood Glucose Monitoring System |
| Classification Name: | Glucose test system (per 21 CFR 862.1345) |
| Class: | II |
| Panel: | Chemistry |
3. Modification Device:
The modification of WaveSense JAZZ™ blood glucose system does not require the user to enter a calibration code.
Therefore, the device is will be marketed as a NO CODING REQUIRED Blood Glucose Monitoring System.
Description of the Device: 4.
The AgaMatrix WaveSense JAZZ™ Blood Glucose Monitoring System includes a meter with batteries, compact carrying case, Lancing device, lancets, control solution and owner's booklet. Test Strips are sold separately.
1
Image /page/1/Picture/0 description: The image shows the word "AgaMatrix" in a simple, sans-serif font. There is a curved line underneath the word, starting below the "A" and ending below the "x". To the right of the word, there are four small, filled squares arranged in a diagonal line.
10 Manor Parkway Salem, NH 03079 Office: +1 (603) 328-6000 Fax: +1 (603) 893-4191
510(k) Summary (Continued)
It is intended for over-the-counter home use by diabetics to monitor their blood glucose levels, or for use in a clinical setting by healthcare professionals. The system tests fresh capillary whole blood. The meter is a portable, battery-operated instrument.
5. Intended use of the device:
The WaveSense JAZZ 100 Blood Glucose Monitoring System in intended to quantitatively measure blood glucose levels, also known as blood sugar, from fresh capillary whole blood samples taken from the fingertips, palm, or forearem. The WaveSense JAZZ TM Test Strips are for in vitro diagnostic (outside of the body) use only. The WaveSense JAZZ TM System is not for intended for use with neonates.
Testing:
The manufacturer of the WaveSense JAZZ TM Blood Glucose Monitoring System certifies that the device complies with the following:
ISO 15197:2003 In vitro diagnostic test systems- Requirements for blood glucose monitoring systems for self-testing in managing diabetes mellitus.
ISO 14971:2000 Medical devices - Application of risk management to Medical devices
IEC 61010-1 Medical electrical equipment - General requirement for safety
I EC 61010-2 Safety requirement for electrical equipment for measurement, control and laboratory use -- particular requirements for in vitro diagnostic (IVD) medical equipment
IEC 61000-403 Electromagnetic compatibility (EMC)
6. Conclusions
Based upon the testing and comparison to the predicate device, the WaveSense JAZZ™ Blood Glucose Monitoring System which does not require coding, has the same intended uses, with similar technological characteristics as the predicate device. The system performs as intended and raises no new safety of effectiveness issues.
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle-like symbol with three curved lines forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the symbol.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
AgaMatrix, Inc. c/o Connie Hertel Director Quality & Regulatory Affairs 10 Manor Parkway Salem. NH 03079
SEP 2 7 2007
Re: K072413
Trade/Device Name: AgaMatrix JAZZ™ Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: NBW, CGA, JJX Dated: August 27, 2007 Received: August 28, 2007
Dear Ms. Hertel:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
3
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a logally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Jean M. Cooper, M.S., D.V.M.
Yean M. Cooper, M.S., D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Indication for Use
510(k) Number (if known): Kb72.413 Device Name: JAZZ™M Indication For Use:
AgaMatrix JAZZTM Blood Glucose Monitoring System:
AgaMatrix JAZZ™ Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood from the finger stick, palm, and/or forearm. Testing is done outside the body (in vitro diagnostic use). It is indicated for use at home (over the counter (OTC) ) by persons with diabetes, or in a clinical setting by healthcare professionals, as an aid to monitor the effectiveness of diabetes control.
AgaMatrix JAZZ™ Blood Glucose Meter:
AgaMatrix JAZZ™ Blood Glucose Meter is intended for use with AgaMatrix JAZZ™ Blood Glucose Test Strips for the quantitative measurement of glucose in fresh capillary whole blood from the finger stick, palm, and/or forearm. Testing is done outside the body (in vitro diagnostic use). It is indicated for use at home (over the counter (OTC) ) by persons with diabetes, or in a clinical setting by healthcare professionals, as an aid to monitor the effectiveness of diabetes control.
AgaMatrix JAZZ™ Blood Glucose Test Strips:
AgaMatrix JAZZ™ Blood Glucose Test Strips are intended for use with AgaMatrix JAZZ™ Blood Glucose Meter for the quantitative measurement of glucose in fresh capillary whole blood from the finger stick, palm and/or forearm. Testing is done outside the body (in vitro diagnostic use). It is indicated for use at home (over the counter (OTC) ) by persons with diabetes, or in a clinical setting by healthcare professionals, as an aid to monitor the effectiveness of diabetes control.
AgaMatrix JAZZTM Control Solutions (Normal level and High level):
AgaMatrix JAZZ™ Control Solutions are intended for use with the AgaMatrix JAZZ™ Meter and AgaMatrix JAZZ™ Test Strips as a quality control check to verify the accuracy of blood glucose test results.
Prescription Use X (21 CFR Part 801 Subpart D)
And/Or
Over the Counter Use X (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) Caro Seman
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K072413